| 000 | 01976cam a2200265 4500500 | ||
|---|---|---|---|
| 005 | 20250112064026.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aLi, Yan _eauthor |
| 700 | 1 | 0 |
_a Zhang, Jimin _eauthor |
| 700 | 1 | 0 |
_a Liu, Xiaoyan _eauthor |
| 700 | 1 | 0 |
_a Ganesan, Kumar _eauthor |
| 700 | 1 | 0 |
_a Shi, Guixiu _eauthor |
| 245 | 0 | 0 | _aIdentification of inflammatory markers as indicators for disease progression in primary Sjögren syndrome |
| 260 | _c2024. | ||
| 500 | _a31 | ||
| 520 | _aPrimary Sjögren syndrome (pSS) is a systemic autoimmune disorder that affects various systems in the body, resulting in symptoms such as dry eyes and mouth, pain, and fatigue. Inflammation plays a critical role in pSS and its associated complications, with chronic inflammation being a common occurrence in patients with pSS. This review of the literature highlights inflammatory markers that could serve as indicators to predict disease progression in pSS. ResultsLaboratory markers are frequently and significantly increased in pSS patients, including erythrocyte sedimentation rate, C-reactive protein, complement proteins, S100 proteins, cytokines (IFNs, CD40 ligand, soluble CD25, rheumatoid factors, interleukins, and TNF-α), and chemokines (CXCL13, CXCL10, CCL2, CXCL11, and CCL25). These inflammatory markers can be used as prognostic indicators for disease progression in pSS. ConclusionIn conclusion, the results from the studies reported in this review indicate that high levels of inflammatory markers may serve as markers for disease progression of pSS, which, in turn, may be valuable in predicting disease outcome. | ||
| 690 | _amarkers of inflammation | ||
| 690 | _aprognosis | ||
| 690 | _acytokines | ||
| 690 | _achemokines | ||
| 690 | _aprimary Sjögren syndrome | ||
| 786 | 0 | _nEuropean Cytokine Network | Volume 35 | 1 | 2024-07-01 | p. 1-12 | 1148-5493 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/revue-european-cytokine-network-2024-1-page-1?lang=en |
| 999 |
_c236197 _d236197 |
||